Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
Navigating the Proposed SEC Rules on Accounting for Obligations to Safeguard Crypto-assets
Background The SEC released Staff Accounting Bulletin No.
Current Expected Credit Losses (CECL): Are You Prepared?
The adoption date for CECL or ASC 326, Financial Instruments – Credit Losses, is fast approaching for private companies, as calendar-year companies are required to adopt CECL on January 1, 2023.
Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.